10 hours ago · TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti ...

8 hours ago · TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti ...

Nov 28, 2023 · Tectonic’s TX000045 Fc-relaxin fusion protein (“TX45”) is a potential best-in-class agent, resulting from protein engineering efforts to overcome the human hormone’s biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose

TX45 is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, relaxin. While the natural hormone is rapidly cleared by the human body, TX45 has been engineered to deliver pharmacologically active levels of relaxin with infrequent dosing.

Nov 11, 2024 · Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)

Nov 11, 2024 · Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)

The Phase 1 study with TX45 in patients with Group 2 PH with HFpEF is a single dose, open-label study to evaluate safety, tolerability and acute hemodynamic effects of intravenous administration of TX45.

Jul 30, 2024 · TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition ...

Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of...

11 hours ago · In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events. In the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary ...